Sarepta to pause gene therapy Elevidys shipments in U.S.

Sarepta Therapeutics said on Monday that it will pause all shipments of its Elevidys gene therapy in the United States after a muscular dystrophy patient who received a different, experimental treatment died.

U.S. regulators on Friday asked Sarepta Therapeutics to voluntarily halt shipments of its gene therapy. However, the company had first refused to do so.

All shipments of Elevidys for Duchenne muscular dystrophy would be temporarily paused by close of business on Tuesday, Sarepta said in a statement.